By Brazil Stock Guide — Brazil’s antitrust tribunal, Cade, will review next Wednesday a proceeding involving Amil and Vision Med, the operator behind the Golden Cross brand, in a case that may clarify how far operational agreements regulated by the national health-plan agency ANS can go before they start raising competition concerns.
The case was included on Cade’s upcoming judgment agenda. It is being handled under restricted access, and the public agenda does not detail the object of the investigation.
At the center of the case is an agreement signed in May 2024 between Amil and Vision Med to share healthcare provider networks. The contract was structured under ANS Normative Resolution No. 517/2022. Under the arrangement, Golden Cross beneficiaries began using Amil’s accredited network, while formally remaining clients of Vision Med.
The structure is sensitive because there was no formal acquisition of a customer portfolio, but Amil began playing a central role in the delivery of healthcare services to Golden Cross beneficiaries. In practice, Vision Med remained the operator of record before clients and ANS, while Amil’s network became the backbone for hospital, outpatient and laboratory care.
Golden Cross entered the agreement from a position of severe financial deterioration. In January 2025, ANS ordered the operator to sell its customer portfolio, which included about 206,300 medical-plan users and 108,000 dental-plan users, within 30 days. In Brazil’s health-plan market, such a measure is often seen as a step that may precede extrajudicial liquidation.
According to a Valor Econômico report at the time, about 95% of Golden Cross health-plan monthly payments were directed to Amil, which was responsible for paying hospitals, clinics and laboratories. The structure suggests that Golden Cross retained formal ownership of the portfolio while transferring a substantial part of the healthcare operation to its partner.
The deterioration later culminated in ANS placing Vision Med into extrajudicial liquidation. The agency cited serious economic, financial and administrative problems, in a context marked by loss of scale, pressure from medical-loss ratios, difficulties in paying providers and growing fragility in ensuring continuity of care.
In a response to Brazil Stock Guide, Amil said the contract was signed “in accordance with the rules of ANS Normative Resolution 517/22” and that network sharing is a “usual market practice.” The company also said the agreement was formally reported to ANS and expressly provided that Vision Med beneficiaries would remain linked to their original operator.
“During the term of the contract and even after its termination, there was no migration or transfer of beneficiaries from one operator to another,” Amil said. “Vision Med beneficiaries always had the option to exercise portability to any operator, according to their individual preferences.”
The company also said the procedures adopted “strictly observed Cade and ANS legislation and regulations” and that all clarifications regarding the transaction were presented to the antitrust authority.
Amil’s defense rests on a key distinction: the contract, it argues, was a regulated network-sharing instrument, with no change of control, no portfolio acquisition and no compulsory transfer of beneficiaries. If Cade accepts that view, the decision could reinforce the argument that healthcare-cooperation arrangements authorized by ANS do not, by themselves, amount to reportable merger-control events.
The open question is whether the economic substance of the contract may change that conclusion. In a sector where scale, accredited networks and risk management are critical, an agreement that shifts the healthcare operation of a distressed operator to a larger rival may produce effects similar to economic integration, even if formal ownership of the contracts remains unchanged.
The Amil-Golden Cross relationship also draws attention because of the history of the groups involved. Golden Cross was founded in 1971 by Milton Afonso and became Brazil’s largest health-plan operator in the 1980s. It later went through successive crises, sold portfolios, lost scale and faced recurring financial problems.
Amil, in turn, is one of Brazil’s largest private health-plan companies. Founded by Edson de Godoy Bueno, it was sold in 2012 to UnitedHealth Group and, at the end of 2023, came under the control of businessman José Seripieri Filho, the founder of Qualicorp.
For Brazil’s private healthcare market, the ruling may matter well beyond this specific case. It could help define where ANS’s regulatory authority ends in network-sharing, risk-management and operational-cooperation arrangements between health-plan operators — and where Cade’s antitrust scrutiny begins.
If Cade concludes that the agreement was not an economic concentration, the decision may provide greater legal certainty for network-sharing models under ANS Resolution 517, especially in cases involving financially distressed operators. If the tribunal takes the opposite view, the ruling may broaden the need for prior antitrust review of similar partnerships in Brazil’s health-plan market.
The case exposes a gray area in Brazil’s supplementary-health system: distressed operators may rely on larger rivals to preserve care for beneficiaries, but those agreements can also reinforce the scale of dominant players and accelerate consolidation without a formal acquisition.
The question before Cade is precisely that: when does an agreement regulated by ANS stop being merely an operational solution to preserve continuity of care and become, in economic terms, a transaction relevant to competition policy?